Literature DB >> 26926636

Reduction in Tedizolid Plasma Exposure among End-Stage Renal Disease Patients Undergoing Dialysis Is Explained by Variations in Ideal Body Weight.

Shawn Flanagan1, Philippe Prokocimer2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26926636      PMCID： PMC4862517          DOI： 10.1128/AAC.03127-15

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


× No keyword cloud information.
  6 in total

1.  The origin of the "ideal" body weight equations.

Authors:  M P Pai; F P Paloucek
Journal:  Ann Pharmacother       Date:  2000-09       Impact factor: 3.154

2.  Tedizolid population pharmacokinetics, exposure response, and target attainment.

Authors:  S Flanagan; J Passarell; Q Lu; J Fiedler-Kelly; E Ludwig; P Prokocimer
Journal:  Antimicrob Agents Chemother       Date:  2014-08-18       Impact factor: 5.191

3.  Pharmacokinetics of tedizolid in subjects with renal or hepatic impairment.

Authors:  S Flanagan; S L Minassian; D Morris; R Ponnuraj; T C Marbury; H W Alcorn; E Fang; P Prokocimer
Journal:  Antimicrob Agents Chemother       Date:  2014-08-18       Impact factor: 5.191

4.  In vivo pharmacodynamics of torezolid phosphate (TR-701), a new oxazolidinone antibiotic, against methicillin-susceptible and methicillin-resistant Staphylococcus aureus strains in a mouse thigh infection model.

Authors:  Arnold Louie; Weiguo Liu; Robert Kulawy; G L Drusano
Journal:  Antimicrob Agents Chemother       Date:  2011-04-18       Impact factor: 5.191

5.  Population pharmacokinetic analysis of linezolid in low body weight patients with renal dysfunction.

Authors:  Yasuhiro Tsuji; Eiji Yukawa; Yoichi Hiraki; Kana Matsumoto; Akiko Mizoguchi; Kunihiko Morita; Hidetoshi Kamimura; Yoshiharu Karube; Hideto To
Journal:  J Clin Pharmacol       Date:  2013-09       Impact factor: 3.126

6.  Population pharmacokinetic analysis of linezolid in patients with infectious disease: application to lower body weight and elderly patients.

Authors:  Sadahiro Abe; Koji Chiba; Brenda Cirincione; Thaddeus H Grasela; Kaori Ito; Toshio Suwa
Journal:  J Clin Pharmacol       Date:  2009-06-23       Impact factor: 3.126
  6 in total
  3 in total

Review 1.  Critical role of tedizolid in the treatment of acute bacterial skin and skin structure infections.

Authors:  Olivia Ferrández; Olatz Urbina; Santiago Grau
Journal:  Drug Des Devel Ther       Date:  2016-12-22       Impact factor: 4.162

Review 2.  Pharmacokinetics and Pharmacodynamics of Tedizolid.

Authors:  Khalid Iqbal; Aliki Milioudi; Sebastian Georg Wicha
Journal:  Clin Pharmacokinet       Date:  2022-02-07       Impact factor: 6.447

Review 3.  Importance and Reality of TDM for Antibiotics Not Covered by Insurance in Japan.

Authors:  Fumiya Ebihara; Yukihiro Hamada; Hideo Kato; Takumi Maruyama; Toshimi Kimura
Journal:  Int J Environ Res Public Health       Date:  2022-02-22       Impact factor: 3.390
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.